510(k) device
iLux Instrument, iLux Disposable
Tear Film Innovations, Inc. · Eyelid Thermal Pulsation System (ORZ, Class II) · First FDA decision Dec 26, 2017, newest Dec 26, 2017Dry eye
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
12
Naming "iLux"
MAUDE reports
5
Brand "iLux", since 2015
PubMed studies
20
Mentioning "iLux"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing iLux Instrument, iLux Disposable
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K172645 · Decided Dec 26, 2017 · 116 days after receipt
Device type: Eyelid Thermal Pulsation System (ORZ) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "iLux", any status and sponsor, newest update first.
- Preoperative iLux on Cataract Surgery Derived Dry Eye Disease Due to Meibomian Gland DysfunctionCompleted
George Washington UniversityAcademic, hospital or other
NCT06483750 · 30 participants · Start Jun 3, 2024 · Primary completion Feb 1, 2025
Device: Systane iLux Treatment · For: Dry Eye Disease; Meibomian Gland Dysfunction; Cataract Senile and 1 more
Sites: Washington D.C., District of Columbia
11 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "iLux", and for the whole product code for context.
This brand
5 reports: 0 malfunction, 5 injury, 0 death
Whole product code ORZ
35 reports: 5 malfunction, 29 injury, 0 death
Newest reports for this brand
ALCON RESEARCH, LLC - IRVINE TECHNOLOGY CENTER
2028159-2024-00940 · Received Jun 28, 2024 · Event dated May 1, 2023
Device type: Eyelid Thermal Pulsation System (ORZ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Corneal Abrasion
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "iLux"[tiab]. The summary above synthesizes these.
- Comparison of Two Thermal Pulsation Systems in the Treatment of Meibomian Gland Dysfunction: A Randomized, Multicenter Study.
Wesley G, Bickle K, Downing J, et al. · Optom Vis Sci · 2022Multicenter Study, Randomized Controlled Trial
- Dry Eye Disease Management Via Technological Methods: A Systematic Review and Network Meta-analysis.
Ben Ephraim Noyman D, Chan CC, Teichman JC, et al. · Ophthalmol Ther · 2025
- The ILux® compared to the mechanical meibomian gland expression for the treatment of moderate and severe meibomian gland dysfunction.
Núñez MX, Acosta-Ortega A, Vera-Duarte GR, et al. · Int J Ophthalmol · 2024
- In-office thermal systems for the treatment of dry eye disease.
Beining MW, Magnø MS, Moschowits E, et al. · Surv Ophthalmol · 2022Review, Research Support, Non-U.S. Gov't
- Longitudinal monitoring of individual infection progression in Drosophila melanogaster.
Ramirez-Corona BA, Love AC, Chandrasekaran S, et al. · iScience · 2022
- Engineered Bioluminescent Nano-Bacteria Biohybrids Powering Self-Driven Photodynamic and Photothermal Synergistic Cancer Treatment.
Zhang Y, Niu L, Jin K, et al. · ACS Appl Mater Interfaces · 2025
- Strongly enhanced bacterial bioluminescence with the ilux operon for single-cell imaging.
Gregor C, Gwosch KC, Sahl SJ, et al. · Proc Natl Acad Sci U S A · 2018Research Support, Non-U.S. Gov't
- Combination of iLux Photothermal Pulsation Therapy with 0.05% Cyclosporine in the Treatment of Meibomian Gland Dysfunction: A Clinical Study.
Xu H, Kang Q · Int J Gen Med · 2025
- Systane iLux Thermal Pulsation System in the Treatment of Meibomian Gland Dysfunction: A Post-Hoc Analysis of a 12-Month, Randomized, Multicenter Study.
Wesley G, Bickle K, Downing J, et al. · Clin Ophthalmol · 2022Case Reports, Clinical Trial
- Generation of bright autobioluminescent bacteria by chromosomal integration of the improved lux operon ilux2.
Gregor C · Sci Rep · 2022Research Support, Non-U.S. Gov't
- Navigating the Dry Eye Therapeutic Puzzle: A Mechanism-Based Overview of Current Treatments.
Betz J, Galor A · Pharmaceuticals (Basel) · 2025Review
- A spectroscopic approach to measuring meibum lipid composition and conformation in donors with Sjӧgren's syndrome.
Ewurum A, Veligandla SR, Swindle JS, et al. · Exp Eye Res · 2021Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code ORZ.
- LipiFlow Thermal Pulsation SystemTearscience, Inc. · 510(k) 2019
- TearCare MGX SystemSight Sciences, Inc. · 510(k) 2026
- TearCare SystemSight Sciences, Inc. · 510(k) 2026
- Tixel i (TXLI0001)Novoxel , Ltd. · 510(k) 2024
- Systane iLux2Tear Film Innovations, Inc. · 510(k) 2020
- Lipflow Thermal Pulsation System (Formerly Manual Mini System)Tearscience, Inc. · De Novo 2011
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.